Can Erectile Dysfunction Be a Fertility Issue?

No. Erectile dysfunction is a problem with getting or keeping an erection. It does not change how many sperm the testes make, how well they move or how they are shaped — those are measured separately, on a semen analysis. What erectile dysfunction interferes with is delivery: it makes intercourse difficult or impossible, and conception is affected only through that.

So there are two separate questions here, with separate answers and separate tests. A man can have a problem with one and not the other, and the only way to know which you are dealing with is to have both checked.

If you are reading this privately, that is the ordinary case rather than the unusual one. In a community survey of 211 men in four villages of Kaniyambadi block, Vellore district, erectile dysfunction was reported by 29.9% and was associated with worry about loss of semen and with the belief that the problem was a punishment (Vivekanandan 2019, Indian Journal of Psychological Medicine). Those beliefs are common and they are not true. They also delay the one thing that settles the question, which is a test.

They are different problems in different parts of the same process.

• Erectile dysfunction is defined by the European Association of Urology as the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance. It is assessed by history, examination, a validated questionnaire such as the IIEF, and blood tests.
• Male infertility is about the sperm — how many there are, how they move, how they are formed. It is assessed by semen analysis. The AUA/ASRM guideline asks for a reproductive history and one or more semen analyses at the initial evaluation (Statement 2).

The practical consequence is that one does not predict the other. A man can have severe erectile dysfunction and an entirely normal semen analysis, and he can have reliable erections and a very low sperm count. Neither result tells you anything about the other, which is why both are assessed rather than one being inferred from the other.

The AUA/ASRM guideline asks for both partners to be assessed at the same time rather than in sequence — Statement 1, an Expert Opinion. If you are deciding who gets tested first, the answer in the guideline is both. What the semen analysis itself reports is set out in what a semen analysis reveals.

Through frequency and timing, and nothing else.

Conception is possible across a window of about six days in the cycle. When two cohorts were re-analysed with a correction for errors in dating ovulation — Catholic couples using natural family planning in London in the 1950s and 1960s, and North Carolina couples in the early 1980s — both gave the same six-day fertile interval, with the highest probability of pregnancy on the day before ovulation and a probability falling close to zero after ovulation (Dunson 1999, Human Reproduction).

That is the whole mechanism. If erectile dysfunction means intercourse does not happen inside that window, the cycle passes without a chance of conception, even when the semen analysis is normal. Nothing has happened to the sperm; the opportunity was missed.

It also explains why trying harder tends to make it worse. Timed intercourse turns sex into a performance with a deadline. The EAU notes that most cases of erectile dysfunction are of mixed cause rather than purely physical or purely psychological, which is why the guideline asks for a targeted psychosexual history covering life stressors and cultural factors, not just blood tests.

This is the real overlap between erectile dysfunction and fertility, and it is not that one causes the other. Both sit downstream of the same conditions, and the erection often complains first. The EAU lists the recognised risk factors as age, diabetes, dyslipidaemia, hypertension, cardiovascular disease, obesity, metabolic syndrome, lack of exercise, smoking and drug use, alongside hormonal causes including low testosterone.

• Diabetes. Pooled prevalence of erectile dysfunction in diabetes was 52.5% (95% CI 48.8-56.2) across 145 studies and 88,577 men, with odds about 3.6 times those of controls (OR 3.62, 95% CI 2.53-5.16) (Kouidrat 2017, Diabetic Medicine). At one Indian tertiary centre, 212 of 357 men with type 2 diabetes had erectile dysfunction (Parmar 2022, Journal of Family Medicine and Primary Care).
• Prediabetes, not only diabetes. Across nine observational studies, men with prediabetes had higher prevalence of erectile dysfunction than men with normal glucose (OR 1.62, 95% CI 1.28-2.07), and the association was stronger in men under 50 than over (Jin 2021, Frontiers in Endocrinology) — that is, in the age band that is trying to conceive.
• Cardiovascular disease. Across 14 cohort studies and 92,757 men followed a mean of 6.1 years, erectile dysfunction preceded total cardiovascular events at a pooled relative risk of 1.44 (95% CI 1.27-1.63) and myocardial infarction at 1.62 (1.34-1.96). The relative risk was higher at younger ages (Vlachopoulos 2013, Circulation: Cardiovascular Quality and Outcomes).

Being young does not exclude you. Among 439 consecutive men seeking medical help for the first time for new-onset erectile dysfunction, 114 of 439 men (26%) were 40 or younger, and severe erectile dysfunction was found in 48.8% of those 114 men — a rate not significantly different from the older group (Capogrosso 2013, Journal of Sexual Medicine). There is more on the metabolic overlap in male fertility and diabetes and what has actually been measured about lifestyle.

The useful way to read this is that erectile dysfunction is worth investigating for what it may be pointing at, not because it is damaging sperm. It is a reason to check glucose, lipids, blood pressure and testosterone — which is exactly what the guideline asks for.

For the erection, see a urologist or an andrologist. For the conception question, both partners are assessed together. The two appointments answer two different questions and neither substitutes for the other.

The EAU makes four Strong recommendations for the first assessment of erectile dysfunction:

1. A comprehensive medical and sexual history, including a targeted psychosexual history covering life stressors and cultural factors.
2. A validated questionnaire such as the International Index of Erectile Function, to record severity and later to measure whether treatment worked.
3. A focused physical examination, to identify underlying conditions and genital disorders.
4. Laboratory tests including glucose, lipid profile and total testosterone, to find reversible risk factors.

On the fertility side, the AUA/ASRM guideline asks for hormonal evaluation including FSH and testosterone specifically in infertile men who have impaired libido, erectile dysfunction, a low or absent sperm count, or small testes (Statement 10, Expert Opinion) — so raising the erection problem at a fertility appointment changes what gets tested.

None of this is invasive. It is a conversation, an examination, a blood test and a semen sample.

This is the single most useful thing on this page to take to an appointment.

The AUA/ASRM guideline states it as a Clinical Principle, Statement 42: "For the male interested in current or future fertility, clinicians should not prescribe exogenous testosterone therapy." Testosterone given from outside suppresses the pituitary signals that drive sperm production, so it can lower the sperm count while appearing to help the symptoms that brought you in.

So say at the first appointment that you are trying to conceive or may want to later, before any prescription is written. What you should not do is stop or change a medicine you have already been prescribed on the strength of a web page — take this to the person who prescribed it. The same applies to low testosterone as a diagnosis; hypogonadism has treatment routes that do not suppress sperm production, and that choice belongs to the clinician who has your results.

The same applies to non-prescribed anabolic steroid use for the gym. A systematic review and meta-analysis of 32 studies covering 9,371 men, of whom 2,671 were users, found lower FSH and LH, lower sperm motility and smaller testicular size in users, with erectile function improving during use and declining on withdrawal (Mulawkar 2023, Journal of Human Reproductive Sciences).

Yes, in most cases, and the order the guideline puts things in is worth knowing.

First, the EAU makes it a Strong recommendation to start lifestyle change and risk-factor modification before or at the same time as any treatment, and rates the evidence that lifestyle change can improve erectile function at level 1a in specific populations. Controlling diabetes and blood pressure is part of treating the erection, not a separate project.

Second, oral PDE5 inhibitors are the first-line drug treatment (EAU, Strong recommendation), with improvement in erectile function and a good overall safety profile at evidence level 1a, and no demonstrated difference in efficacy between the four licensed agents. These are prescription medicines with real interactions — they are contraindicated with nitrates — and the choice, dose and timing belong to a clinician. The EAU also notes that incorrect use and inadequate information are the main causes of an apparent lack of response, which is a reason to ask questions rather than to conclude the drug does not work for you. Where there is a psychological component, the EAU recommends cognitive behaviour therapy alongside medical treatment, with the partner included where appropriate. Other options exist when oral treatment is unsuitable or ineffective, and a urologist will set those out.

Where intercourse remains impossible, conception does not depend on it. Sperm can be collected and placed directly: intrauterine insemination where the semen analysis supports it, or ICSI where it does not — the AUA/ASRM guideline notes that with a low total motile sperm count on repeated analyses, IUI success rates may be reduced and IVF or ICSI may be considered (Statement 39). The difference between IVF and ICSI matters here, and it is decided on the semen analysis rather than on the erection.

It is also worth saying plainly that IVF is often not the answer to this problem. If the semen analysis is normal and the erection is treatable, then treating the erection and getting the timing right is the whole intervention.

Several things are widely written about this topic that the sources above do not support.

• That erectile dysfunction damages sperm. No source here shows that. What is measured is an association in the other direction as well: across eight controlled studies, the pooled odds of sexual dysfunction were about 2.7 times higher in infertile men than in controls (OR 2.66, 95% CI 1.69-4.19), with substantial heterogeneity (I-squared 67%) (Liu 2022, Sexual Medicine). An observational association cannot say which came first, and an infertility diagnosis followed by months of timed intercourse is itself a plausible cause of erectile dysfunction rather than a consequence of it.
• That treating erectile dysfunction improves sperm quality. Not measured in anything cited here. Treating the underlying diabetes is a different claim from treating the erection, and neither was assessed for its effect on semen parameters in these sources.
• That erectile dysfunction predicts cardiovascular death. The meta-analysis above concludes that erectile dysfunction is associated with cardiovascular events and all-cause mortality, but its own result for cardiovascular mortality specifically was a relative risk of 1.19 with a 95% confidence interval of 0.97 to 1.46 — it crossed 1. Total cardiovascular events and myocardial infarction did not.
• That there is one prevalence figure for erectile dysfunction. It depends heavily on how the question is asked. The EAU cites the Massachusetts Male Aging Study at 52% prevalence in men aged 40-70 versus the Cologne study at 19.2% in men aged 30-80, and the meta-analysis above found risk estimates higher when erectile dysfunction was measured by questionnaire than by a single question.
• A representative Indian figure. The two Indian studies cited here are a 211-man survey in four villages of one Vellore block and a 357-man series from one diabetes clinic. Neither is nationally representative, and no national prevalence estimate for Indian men of reproductive age was found.

Where a number is missing above, it is missing because it was not found, not because it was left out.